One Biosciences
- Company typePrivate
- Founded2020
- HeadquartersParis, France
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
One Biosciences firmographics
Firmographics- Name
- One Biosciences
- Legal name
- One Biosciences SAS
- Website
- https://onebiosciences.fr/
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
One Biosciences industry classification
Industry- Product category
- Precision Oncology Diagnostics
- NAICS
- Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Single-Cell & Spatial Omics Services (HLAGANAC), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where One Biosciences is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
One Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Clinical Diagnostic Services: The company provides clinical-grade single-cell profiling services to healthcare providers and clinical institutions, delivering tumor analysis reports in under two weeks to support oncologists with treatment decision-making.
- Pharma & Biotech Partnership Services: B2B services for pharmaceutical and biotech companies including biomarker identification, patient stratification, clinical trial optimization, and target prioritization. Revenue generated through research collaborations, co-development agreements, and service contracts.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
One Biosciences product offering
Product offeringCore offering
One Biosciences operates the OneMap platform, an AI-powered clinical-grade single-cell transcriptomic profiling service that processes FFPE or frozen tissue samples to generate high-quality profiles of tumor, stromal, and immune cells, delivering clinician-ready reports in under two weeks. The company sells these profiling services to pharmaceutical and biotech companies for biomarker identification, patient stratification, and clinical trial support, and to clinical oncology institutions for treatment decision-making.
Product overview
One Biosciences offers a unified platform called OneMap for AI-powered, clinical-grade single-cell profiling in precision oncology. The platform comprises the core OneMap Platform for single-cell transcriptomic analysis, which includes two integrated modules: Clinical Tumor Intelligence for oncologist decision support and Pharma & Biotech Partner Platform for drug development applications. The company also provides MAYA, a computational method for multi-modal pathway analysis published in Nature Communications. The platform processes clinical samples (FFPE or frozen tissue) and delivers clinician-ready reports in under two weeks using clinically trained AI foundation models.
Differentiator
Problem solved
Functional benefit
Brands
- OneMap: Clinical-grade single-cell transcriptomic oncology platform that generates high-quality profiles of tumor, stromal and immune cells from clinical samples, delivering reports in under two weeks.
Products and services
- OneMap Platform
- Clinical Diagnostic Services
- Pharma & Biotech Partnership Services
Quantifiable outcome
- Clinical-grade reports delivered in under two weeks
- +2 more outcomes
Companies that use One Biosciences
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
One Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
One Biosciences partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- AdcytherixcoreCollaboration partner in BOOST grant project to develop single-cell assay for ADC therapies. Combines Adcytherix's antibody-drug conjugate development expertise with One Biosciences' AI-powered single-cell profiling technology to analyze tumor samples and identify biomarkers associated with treatment response in oncology.
- Gustave RoussycoreMajor partnership to implement single-cell analysis into clinical oncology practice using AI-powered solutions to predict treatment responses in cancer patients. Collaboration builds on previous feasibility studies with focus on integrating ultra-high-resolution tumor data into patient care workflows. Also collaborated on bladder cancer research project (April 2024) and urothelial cancer study presented at AACR 2025.
- Institut CuriecoreFounding institution where One Biosciences originated in 2017. Co-founder Céline Vallot heads the Dynamics of Epigenetic Plasticity group at Institut Curie. The company was created to turn proof-of-concept from Institut Curie research into a commercial platform. Institut Curie provided startup incubation support starting March 2021.
- AP-HP (Assistance Publique-Hôpitaux de Paris)minorPartnership to launch a single-cell research project on a rare kidney disease announced in November 2023, expanding the company's disease area focus beyond oncology.
- Home BiosciencescoreStrategic partner and incubator. Co-founders Magali Richard and David Schilansky from Home Biosciences helped sharpen the company's vision to make single-cell work on real clinical samples. Home Biosciences provided incubation support for company creation in 2020.
Scale indicators3 records
Recent moves9 records
Expansion highlights6 records
One Biosciences competitors and assessment
Company assessmentDirect peers
- 10x Genomics: Leading provider of single-cell sequencing platforms (Chromium, Visium) used widely across academic and pharma oncology research. Direct competitor to OneMap in clinical single-cell profiling, with a much larger installed base and broader assay portfolio.
- Parse Biosciences: Single-cell RNA sequencing platform provider with scalable, fixation-based workflows (Evercode) that, like One Biosciences, target flexibility in sample handling for clinical and translational research. Comparable technology category and customer overlap in pharma biomarker discovery.
- Mission Bio: Single-cell multi-omics platform focused on oncology applications including measurable residual disease and tumor heterogeneity — directly adjacent to One Biosciences' clinical single-cell oncology positioning, with overlapping pharma/biotech and clinical customer base.
- NanoString Technologies (Bruker Spatial Biology): Provider of spatial transcriptomics and single-cell profiling solutions (GeoMx, CosMx) for oncology research and translational applications. Overlaps with One Biosciences on tumor microenvironment profiling and pharma biomarker services.
Broad incumbents
- Foundation Medicine (Roche): Established molecular diagnostics company providing comprehensive genomic profiling of solid tumors — a broad incumbent in clinical oncology diagnostics whose executive chairman (Dr. Vincent Miller) previously served as CMO. Compares as a large-scale reference point for clinical-grade tumor profiling and pharma partnerships.
- Tempus Labs: AI-driven precision medicine company combining multi-omics sequencing with clinical data for oncology decision support and pharma R&D — a broad incumbent whose OneMap-relevant overlap includes clinical tumor profiling and pharma data services, and which acquired Ambry Genetics (former employer of One's CBO).
- Caris Life Sciences: Molecular profiling and AI-driven precision oncology company offering whole-exome, whole-transcriptome, and proteomic tumor analysis plus pharma services. Comparable in clinical tumor intelligence and pharma/CDx partnership model.
Emerging players
- Akoya Biosciences: Specialist in spatial biology (PhenoCycler, PhenoImager) for tumor microenvironment characterization in research and clinical pharma. Emerging peer with partial overlap on single-cell/spatial tumor profiling for pharma biomarker work.
- Personalis: Cancer genomics company offering tumor profiling assays (e.g., NeXT Personal) for minimal residual disease and immunotherapy response monitoring. Comparable as a clinical-grade, pharma-services-oriented oncology genomics player.
- Nucleai: AI-driven spatial biology company providing tumor microenvironment analysis for pharma drug development. Directly comparable in AI-oncology focus; CBO Vikas Ahuja previously led strategic partnerships there.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
One Biosciences social profiles
Digital presenceOne Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
One Biosciences leadership team
Management profileNumber of profiles
Profiles9 records
One Biosciences funding detail
Funding detailFunding overview
Funding rounds5 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
One Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about One Biosciences
What does One Biosciences do?
One Biosciences operates the OneMap platform, an AI-powered clinical-grade single-cell transcriptomic profiling service that processes FFPE or frozen tissue samples to generate high-quality profiles of tumor, stromal, and immune cells, delivering clinician-ready reports in under two weeks. The company sells these profiling services to pharmaceutical and biotech companies for biomarker identification, patient stratification, and clinical trial support, and to clinical oncology institutions for treatment decision-making.
Is One Biosciences a public or private company?
One Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was One Biosciences founded?
One Biosciences was founded in 2020. It employs 1 to 10 people.
Where is One Biosciences based?
One Biosciences is headquartered in Paris, France, in the Europe region.
How does One Biosciences make money?
Two revenue lines are on record. Clinical Diagnostic Services are the primary driver. The others are pharma & Biotech Partnership Services.
Who are One Biosciences's main competitors?
Direct peers on record are 10x Genomics, Parse Biosciences, Mission Bio and NanoString Technologies (Bruker Spatial Biology). Broad incumbents are Foundation Medicine (Roche), Tempus Labs and Caris Life Sciences. Emerging players are Akoya Biosciences, Personalis and Nucleai.
Does One Biosciences have an API?
No public API is recorded for One Biosciences.
What industry is One Biosciences in?
One Biosciences's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAGANAC, Single-Cell & Spatial Omics Services. Its NAICS code is 621511 and its SIC code is 8071.